{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:02Z","timestamp":1790796182243,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jvacx.2024.100595","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T17:39:23Z","timestamp":1733506763000},"page":"100595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA\u00ae02 and SOBERANA\u00ae Plus in children 3\u201318 years old"],"prefix":"10.1016","volume":"22","author":[{"given":"Dagmar","family":"Garc\u00eda-Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinaldo","family":"Puga-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsire","family":"Fern\u00e1ndez-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Paredes-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yariset","family":"Ricardo-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiby","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Valenzuela","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocmira","family":"P\u00e9rez-Nicado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rodr\u00edguez-Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darielys","family":"Santana-Mederos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanet","family":"Climent-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Noa-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Cruz-Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"S\u00e1nchez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tays","family":"Hern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Palenzuela-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisel","family":"Mart\u00ednez-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arilia","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Vald\u00e9s-Balb\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente G.","family":"V\u00e9rez-Bencomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jvacx.2024.100595_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.7822","article-title":"COVID-19 vaccination and incidence of pediatric SARS-CoV-2 infection and hospitalization","volume":"7","author":"Head","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvacx.2024.100595_bb0010","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1038\/s41467-024-47745-z","article-title":"Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England","volume":"15","author":"Copland","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jvacx.2024.100595_bb0015","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1177\/10600280231156625","article-title":"A review of the data supporting use of COVID-19 vaccinations in the pediatric population","volume":"57","author":"Stultz","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvacx.2024.100595_bb0020","author":"W.H.O"},{"key":"10.1016\/j.jvacx.2024.100595_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2024.100750","article-title":"Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2\u201311 years-old children during the SARS-CoV-2 omicron wave in Cuba: a longitudinal case-population study","volume":"34","author":"Toledo-Romani","year":"2024","journal-title":"Lancet Regional Health \u2013 Americas"},{"key":"10.1016\/j.jvacx.2024.100595_bb0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/vaccines12030326","article-title":"Comparative analysis of SARS-CoV-2 antibody responses across global and lesser-studied vaccines","volume":"12","author":"Zambrana","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.jvacx.2024.100595_bb0035","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1002\/jmv.27962","article-title":"Pediatric and adolescent COVID-19 vaccination side effects: a retrospective cohort study of Iranian teenage group in 2021","volume":"94","author":"Tavakoli","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.jvacx.2024.100595_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medj.2022.08.001","article-title":"Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA plus vaccines: phase IIb clinical trial in adults","volume":"3","author":"Toledo-Romani","year":"2022","journal-title":"Med"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100595_bb0045","article-title":"Efficacy and safety of a protein-based SARS-CoV-2 vaccine. A randomized clinical trial","volume":"6","author":"Mostafavi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jvacx.2024.100595_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100423","article-title":"Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial","volume":"18","author":"Toledo-Romani","year":"2023","journal-title":"Lancet Regional Health \u2013 Americas"},{"key":"10.1016\/j.jvacx.2024.100595_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijid.2022.11.016","article-title":"Open label phase I\/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children","volume":"126","author":"Puga","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jvacx.2024.100595_bb0060","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3390\/vaccines11111636","article-title":"Comparative Immune Response after Vaccination with SOBERANA\u00ae 02 and SOBERANA\u00ae plus Heterologous Scheme and Natural Infection in Young Children","volume":"11","author":"P\u00e9rez-Nicado","year":"2023","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.jvacx.2024.100595_bb0065","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/vaccines10040492","article-title":"Durability and cross-reactivity of SARS-CoV-2 mRNA vaccine in adolescent children","volume":"10","author":"Burns","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jvacx.2024.100595_bb0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41467-024-45181-7","article-title":"Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination","volume":"15","author":"Nziza","year":"2024","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jvacx.2024.100595_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.vaccine.2023.12.006","article-title":"Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5\u201311 years old children with prior COVID-19","volume":"42","author":"Di Chiara","year":"2024","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.jvacx.2024.100595_bb0080","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvacx.2024.100595_bb0085","author":"Portal-Miranda"},{"key":"10.1016\/j.jvacx.2024.100595_bb0090","article-title":"Postvaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: a retrospective, single-center study","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2024.100595_bb0095","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1038\/s41598-022-07741-z","article-title":"Persistent spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine","volume":"12","author":"Agrati","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jvacx.2024.100595_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl5344","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jvacx.2024.100595_bb0105","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.3390\/vaccines10101646","article-title":"Immunogenicity of a fractional dose of mRNA BNT162b2 COVID-19 vaccine for primary series and booster vaccination among healthy adolescents","volume":"10","author":"Puthanakit","year":"2022","journal-title":"Vaccines"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136224001682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T13:58:02Z","timestamp":1737727082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136224001682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"alternative-id":["S2590136224001682"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100595","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA\u00ae02 and SOBERANA\u00ae Plus in children 3\u201318 years old","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2024.100595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100595"}}